Lupus

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kalled, S L
Right arrow Articles by Ferrant, J L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kalled, S L
Right arrow Articles by Ferrant, J L
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Lupus, Vol. 10, No. 1, 9-22 (2001)
DOI: 10.1191/096120301668384751

Long-term anti-CD154 dosing in nephritic mice is required to maintain survival and inhibit mediators of renal fibrosis

S L Kalled

Department of Inflammation, Biogen Inc., Cambridge, Massachusetts, USA; Biogen Inc., 14 Cambridge Center, Cambridge, MA 02142, USA Susan_Kalled{at}Biogen.com

A H Cutler

Department of Inflammation, Biogen Inc., Cambridge, Massachusetts, USA

J L Ferrant

Department of Protein Chemistry, Biogen Inc., Cambridge, Massachusetts, USA

The CD154=CD40 pathway is required for the development and progression of disease in a variety of autoimmune model systems. We have demonstrated previously that long-term anti-CD154 treatment of nephritic (SWRxNZB)F1 mice prolonged survival and preserved kidney function. Herein we ask if long-term treatment is required and further characterize the protective effect on renal pathology by examining a-smooth muscle actin, collagen and TGF-b1 expression in renal tissue. The effects of anti-CD154 on brain and heart inflammation are also examined. Three dosing strategies of anti-CD154 mAb were compared in SNF1 mice that exhibited moderate or severe nephritis: (1) weekly for 6 weeks; (2) monthly; (3) weekly for 6-12 weeks followed by monthly dosing. Proteinuria, serum anti-DNA, anti-CD154 pharmacokinetics and serum soluble CD154 analyses were performed. Anti-CD154 treatment of moderate disease increased survival across all regimens, although weekly followed by monthly maintenance dosing proved most efficacious. This regime also inhibited renal a-smooth muscle actin and collagen deposition. Only the most aggressive anti-CD154 treatment protocol increased survival in severely nephritic mice.

Long-term anti-CD154 treatment significantly inhibits key mediators of kidney fibrosis and is required to maximize survival and renal function. Potential reasons for differential therapeutic efficacy in moderately vs severely nephritic mice are discussed.

Key Words: lupus • nephritis • CD40 • CD154 • autoimmunity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
L E Schiffer, N Hussain, X Wang, W Huang, J Sinha, M Ramanujam, and A Davidson
Lowering anti-dsDNA antibodies--what's new?
Lupus, December 1, 2002; 11(12): 885 - 894.
[Abstract] [PDF]

Home page
 LupusHome page
M L Huggins, I Todd, and R J Powell
CD40 Ligand--an important target for immunotherapy?
Lupus, January 1, 2001; 10(1): 1 - 3.
[PDF]